Last update 16 May 2025

Azilsartan/Pioglitazone Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Azilsartan/pioglitazone, Pioglitazone/azilsartan, Pioglitazone/TAK 536
+ [3]
Target
AT1R x PPARγ
Action
antagonists, agonists
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists)
Therapeutic Areas
Cardiovascular DiseasesEndocrinology and Metabolic Disease
Active Indication-
Inactive Indication
Diabetes Mellitus, Type 2Hypertension
Originator Organization
Takeda Pharmaceutical Co., Ltd.Takeda Pharmaceutical Co., Ltd.
Active Organization-
Inactive Organization
Takeda Global Research & Development Center, Inc.Takeda Pharmaceutical Co., Ltd.Takeda Pharmaceutical Co., Ltd.
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H21ClN2O3S
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N
CAS Registry112529-15-4
View All Structures (2)

Related

1
Clinical Trials associated with Azilsartan/Pioglitazone Hydrochloride
NCT01124656
/ TerminatedPhase 3
A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of AD 4833-536 in Subjects With Type 2 Diabetes
100 Clinical Results associated with Azilsartan/Pioglitazone Hydrochloride
Login to view more data
100 Translational Medicine associated with Azilsartan/Pioglitazone Hydrochloride
Login to view more data
100 Patents (Medical) associated with Azilsartan/Pioglitazone Hydrochloride
Login to view more data
100 Deals associated with Azilsartan/Pioglitazone Hydrochloride
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3-
Takeda Pharmaceutical Co., Ltd.Takeda Pharmaceutical Co., Ltd.
01 Sep 2006
HypertensionPhase 3
United States
Takeda Global Research & Development Center, Inc.
-
HypertensionPhase 3-
Takeda Pharmaceutical Co., Ltd.Takeda Pharmaceutical Co., Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free